Pretomanid (PA-824)
187235-37-6
≥95%
359
(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (3S)-8-nitro-3-[[4-(trifluoromethoxy)phenyl]methoxy]-5-oxa-1,7-diaza
- Data sheet: View or download
- MSDS: View or download
Pretomanid is a nitroimidazopyran active againt Mycobacterium tuberculosis. It is active against multidrug-resistant M. tuberculosis clinical isolates with MIC <1 µg/ml. Pretomanid at 25, 50, and 100 mg/kg of body weight daily for 10 days or 60 days reduces the mycobacterial burden in both spleen and lung tissue in a mouse infection model. Pretomanid at 100 mg/kg in cyclodextrin/lecithin reduces the bacterial load below 500 CFU in the lungs and spleen. It is approved for use in combination treatment for drug-resistant, treatment-intolerant or non-responsive multidrug-resistant (MDR) Tuberculosis.
-20°C
